Krystal Biotech, Inc. (KRYS) Institutional Ownership

Ownership Summary

Krystal Biotech, Inc. (NASDAQ:KRYS) has 326 institutional investors with active 13F positions as of December 2025.

• Their combined ownership stood at 93.3% of outstanding shares in December 2025, down from 94.9% in September 2025.
• They increased total shares held in KRYS by 1.26% quarter over quarter, and investors in Krystal Biotech increased 25.38% from a year ago.
• During the quarter, 188 of these 326 funds increased positions in KRYS, 104 reduced exposure, and 34 held steady.
• Altogether, these fund groups held 27.96Mn shares in KRYS by December 2025, up by 348.91K shares quarter on quarter, and down 452.57K shares year over year.
• FMR LLC is the top holder of Krystal Biotech as of December 31, 2025, with 4.37Mn shares representing 14.6% of outstanding stock.
• Leading buyers of Krystal Biotech shares for the quarter ending December 2025 were VANGUARD PORTFOLIO MANAGEMENT LLC (1.46Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.17Mn), PRICE T ROWE ASSOCIATES INC /MD/ (485.07K), Janus Henderson Group Plc (313.88K), Soleus Capital Management, L.P. (212.03K).
• The largest sales of KRYS for the quarter ending December 2025 came from Avoro Capital Advisors LLC (2.89Mn), CITADEL ADVISORS LLC (383.78K), Goldman Sachs Group Inc (372.1K), MARSHALL WACE, LLP (115.41K), Corient Private Wealth LLC (73.11K).
• Business Quant data shows the 10 biggest positions in Krystal Biotech as of December 2025 are held by FMR LLC (4.37Mn), BlackRock, Inc. (3.94Mn), Avoro Capital Advisors LLC (2.89Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (1.46Mn), State Street Corp (1.31Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.17Mn), Soleus Capital Management, L.P. (1.15Mn), Capital World Investors (824.72K), Redmile Group, LLC (673.5K), GEODE CAPITAL MANAGEMENT, LLC (643.98K).